اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,720
تعداد مقالات30,985
تعداد مشاهده مقاله26,770,388
تعداد دریافت فایل اصل مقاله16,127,086
Razavi-Nikoo, H, Behboudi, E, Aghcheli, B, Hashemi, S. M. A, Moradi, A. (1402). Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine. سامانه مدیریت نشریات علمی, 78(3), 997-1003. doi: 10.22092/ari.2023.361975.2708
H Razavi-Nikoo; E Behboudi; B Aghcheli; S. M. A Hashemi; A Moradi. "Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine". سامانه مدیریت نشریات علمی, 78, 3, 1402, 997-1003. doi: 10.22092/ari.2023.361975.2708
Razavi-Nikoo, H, Behboudi, E, Aghcheli, B, Hashemi, S. M. A, Moradi, A. (1402). 'Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine', سامانه مدیریت نشریات علمی, 78(3), pp. 997-1003. doi: 10.22092/ari.2023.361975.2708
Razavi-Nikoo, H, Behboudi, E, Aghcheli, B, Hashemi, S. M. A, Moradi, A. Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine. سامانه مدیریت نشریات علمی, 1402; 78(3): 997-1003. doi: 10.22092/ari.2023.361975.2708

Bac to Bac System Efficiency for Preparing HPV Type 16 Virus-Like Particle Vaccine

Archives of Razi Institute
مقاله 27، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 997-1003    اصل مقاله (545.26 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2023.361975.2708
نویسندگان
H Razavi-Nikoo1؛ E Behboudi2؛ B Aghcheli1؛ S. M. A Hashemi1؛ A Moradi* 1
1Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran
2Department of Basic Sciences, Khoy University of Medical Sciences, Khoy, Iran
چکیده
Today, the human papillomavirus (HPV) L1 protein is the main target in the construction of prophylactic HPV vaccines. The production of virus-like particles (VLPs) that closely resemble the natural structure of the HPV16 virus and induce high levels of virus-neutralizing antibodies in animals and humans is facilitated by the expression of HPV16-L1 protein in eukaryotic cells. The Bac-to-Bac system has been previously used to produce high levels of recombinant proteins. In this study, we utilized this expression system to generate HPV16-L1 VLPs in Spodoptra frugipedra (Sf9) insect cells. The wild-type L1 gene of papillomavirus type 16 was selected from Gene Bank and placed in bacmid structure after codon optimization using pFast Bac vector. The recombinant baculovirus containing HPV-16/L1 gene was then provided using the Bac-to-Bac system. It should be mentioned that the vector was transfected into the Sf9 cell. The cells were then lysed and the expression of L1 protein was revealed by SDS-PAGE and confirmed by Western Blot. The L1 purification was performed through Ni-NTA chromatography. The VLP formation of papillomavirus L1 protein was visualized by transmission electron microscopy. The expressed recombinant L1 was ~60 KD on SDS-PAGE which was identified in western blot by a specific anti-L1 monoclonal antibody. The electron microscopy confirmed the assembly of VLPs. Results of this study showed that the production of this protein at the industrial level can be optimized using a baculovirus/Sf9 system. The characteristics and advantages of this system are promising and it is a suitable candidate for protein synthesis.
کلیدواژه‌ها
Baculovirus؛ HPV؛ L1؛ Protein purification؛ Sf9؛ Vaccine
عنوان مقاله [English]
اثربخشی سیستم بیانی Bac to Bac در تولید واکسن پاپیلوما
سایر فایل های مرتبط با مقاله
مراجع
  1. Behboudi E, Mokhtari-Azad T, Yavarian J, Ghavami N, Seyed Khorrami SM, Rezaei F, et al. Molecular detection of HHV1-5, AAV and HPV in semen specimens and their impact on male fertility. Hum Fertil. 2019;22(2):133-8.
  2. Aggarwal P. HPV Infection: Pathogenesis and Detection. Preventive Oncology for the Gynecologist: Springer; 2019. p. 101-15.
  3. Mohebbi E, Hadji M, Rashidian H, Rezaianzadeh A, Marzban M, Haghdoost AA, et al. Opium use and the risk of head and neck squamous cell carcinoma. Int J Cancer. 2021;148(5):1066-76.
  4. Sadr-Momtaz S, Aftabi M, Behboudi E, Naderi M, Hashemzadeh-Omran A, Moradi A. NSP4 as Adjuvant for Immunogenicity and Design of Effective Therapeutic HPV16 E6/E7/L1 DNA Vaccine in Tumoric and Healthy C57BL/6 Mice. 2021.
  5. Shen-Gunther J, Cai H, Zhang H, Wang Y. Abundance of HPV L1 intra-genotype variants with capsid epitopic modifications found within low-and high-grade Pap smears with potential implications for vaccinology. Front Genet. 2019;10:489.
  6. Gholipour M, Islami F, Roshandel G, Khoshnia M, Badakhshan A, Moradi A, et al. Esophageal cancer in Golestan Province, Iran: a review of genetic susceptibility and environmental risk factors. Middle East J Dig Dis. 2016;8(4):249.
  7. Ghaffari SR, Sabokbar T, Mollahajian H, Dastan J, Ramezanzadeh F, Ensani F, et al. Prevalence of human papillomavirus genotypes in women with normal and abnormal cervical cytology in Iran. Asian Pac J Cancer Prev. 2006;7(4):529-32.
  8. Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32):4761-7.
  9. Wang D, Li Z, Xiao J, Wang J, Zhang L, Liu Y, et al. Identification of broad-genotype HPV L2 neutralization site for pan-HPV vaccine development by a cross-neutralizing antibody. PLoS One. 2015;10(4):e0123944.
  10. Mariz FC, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai MR, et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020;5(1):1-6.
  11. Felberbaum RS. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotech J. 2015;10(5):702-14.
  12. Lin S-Y, Chung Y-C, Hu Y-C. Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines. 2014;13(12):1501-21.
  13. Green MR, Hughes H, Sambrook J, MacCallum P. Molecular cloning: a laboratory manual. Molecular cloning: a laboratory manual. 2012. p. 1890.
  14. Abdoli A, Soleimanjahi H, Fotouhi F, Teimoori A, Beiranvand SP, Kianmehr Z. Human papillomavirus type16-L1 VLP production in insect cells. Iran J Basic Med Sci. 2013;16(8):891.
  15. Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Current problems in cancer. 2018;42(5):457-65.
  16. Magaña‐Contreras M, Contreras‐Paredes A, Chavez‐Blanco A, Lizano M, Cruz‐Hernandez YDl, Cruz‐Hernandez EDl. Prevalence of sexually transmitted pathogens associated with HPV infection in cervical samples in a Mexican population. J Med Virol. 2015;87(12):2098-105.
  17. Caulfield MJ, Shi L, Wang S, Wang B, Tobery TW, Mach H, et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin. 2007;3(4):139-45.
  18. Mo X, Tobe RG, Wang L, Liu X, Wu B, Luo H, et al. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17(1):1-12.
  19. Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1(5):408-19.
  20. Jeudin P, Liveright E, Del Carmen MG, Perkins RB. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin Ther. 2014;36(1):24-37.
  21. Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review. PloS One. 2014;9(3):e90912.
  22. Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv. 2012;30(5):1102-7.
  23. Kesidis A, Depping P, Lodé A, Vaitsopoulou A, Bill RM, Goddard AD, et al. Expression of eukaryotic membrane proteins in eukaryotic and prokaryotic hosts. Methods. 2020;180:3-18.
  24. Kwang TW, Zeng X, Wang S. Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials. Mol Ther Methods Clin Dev. 2016;3:15050.
  25. Gupta K, Tölzer C, Sari-Ak D, Fitzgerald DJ, Schaffitzel C, Berger I. Multibac: baculovirus-mediated multigene DNA cargo delivery in insect and mammalian cells. Viruses. 2019;11(3):198.
  26. Mehalko JL, Esposito D. Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells. J Biotechnol. 2016;238:1-8.
  27. Zhai Y, Zhang D, Yu L, Sun F, Sun F. SmartBac, a new baculovirus system for large protein complex production. J Struct Biol: X. 2019;1:100003.
  28. Lemaitre RP, Bogdanova A, Borgonovo B, Woodruff JB, Drechsel DN. FlexiBAC: a versatile, open-source baculovirus vector system for protein expression, secretion, and proteolytic processing. BMC Biotechnol. 2019;19(1):1-11.
  29. Tao Y, Li G, Zheng W, Shu J, Chen J, Yang F, et al. Development of a combined genetic engineering vaccine for porcine circovirus type 2 and Mycoplasma hyopneumoniae by a baculovirus expression system. Int J Mol Sci. 2019;20(18):4425.
  30. Dai X, Jian C, Na L, Wang X, Dai Y, Li D. Production and characterization of Hantaan virus-like particles from baculovirus expression system. Biochem Eng J. 2019;152:107373.
  31. Mabashi-Asazuma H, Jarvis DL. CRISPR-Cas9 vectors for genome editing and host engineering in the baculovirus–insect cell system. Proc Natl Acad Sci U S A. 2017;114(34):9068-73.
آمار
تعداد مشاهده مقاله: 813
تعداد دریافت فایل اصل مقاله: 121


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب